Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215955 · ClinicalTrials.gov registry record · Phase 4
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,117
- Enrollment target
NCT01215955 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,117 participants.
The verdict
NCT01215955, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,117 participants
- Enrollment target
Study Summary
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.
Interventions
- DRUG Insulin lispro
- DRUG Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,117 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215955
The ClinicalTrials.gov registry entry for NCT01215955 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin lispro is the first listed.
NCT01215955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215955 about?
NCT01215955 is a clinical study titled "Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes". Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on...
What is the current status of trial NCT01215955?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,117 participants. The study started on 2010-12. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01215955?
The interventions under investigation include: Insulin lispro (DRUG), Glargine (DRUG).
Who is sponsoring clinical trial NCT01215955?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.